vs
IDACORP INC（IDA）とPHIBRO ANIMAL HEALTH CORP（PAHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
PHIBRO ANIMAL HEALTH CORPの直近四半期売上が大きい（$373.9M vs $360.1M、IDACORP INCの約1.0倍）。IDACORP INCの純利益率が高く（12.1% vs 7.3%、差は4.8%）。PHIBRO ANIMAL HEALTH CORPの前年同期比売上増加率が高い（20.9% vs -4.2%）。PHIBRO ANIMAL HEALTH CORPの直近四半期フリーキャッシュフローが多い（$8.3M vs $-216.2M）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs -7.2%）
IDACORP, Inc.はアメリカ・アイダホ州に法人登録され、本社をボイシに置く電力持株会社です。1998年10月1日に設立され、傘下にアイダホパワー社、IDACORPフィナンシャル社、アイダウエストエナジー社を有し、電力供給、エネルギーサービス、関連金融事業を手がけています。
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
IDA vs PAHC — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $360.1M | $373.9M |
| 純利益 | $43.6M | $27.5M |
| 粗利率 | — | 35.5% |
| 営業利益率 | 14.9% | 13.5% |
| 純利益率 | 12.1% | 7.3% |
| 売上前年比 | -4.2% | 20.9% |
| 純利益前年比 | 15.1% | 762.1% |
| EPS（希薄化後） | $0.78 | $0.67 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $360.1M | $373.9M | ||
| Q3 25 | $526.4M | $363.9M | ||
| Q2 25 | $449.3M | $378.7M | ||
| Q1 25 | $411.1M | $347.8M | ||
| Q4 24 | $375.9M | $309.3M | ||
| Q3 24 | $532.5M | $260.4M | ||
| Q2 24 | $442.6M | $273.2M | ||
| Q1 24 | $417.9M | $263.2M |
| Q4 25 | $43.6M | $27.5M | ||
| Q3 25 | $124.4M | $26.5M | ||
| Q2 25 | $95.8M | $17.2M | ||
| Q1 25 | $59.6M | $20.9M | ||
| Q4 24 | $37.9M | $3.2M | ||
| Q3 24 | $113.6M | $7.0M | ||
| Q2 24 | $89.5M | $752.0K | ||
| Q1 24 | $48.2M | $8.4M |
| Q4 25 | — | 35.5% | ||
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 29.0% | ||
| Q1 25 | — | 30.1% | ||
| Q4 24 | — | 32.9% | ||
| Q3 24 | — | 32.1% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 30.2% |
| Q4 25 | 14.9% | 13.5% | ||
| Q3 25 | 27.5% | 14.1% | ||
| Q2 25 | 22.4% | 8.9% | ||
| Q1 25 | 13.4% | 9.6% | ||
| Q4 24 | 11.0% | 8.3% | ||
| Q3 24 | 25.1% | 6.8% | ||
| Q2 24 | 23.3% | 6.7% | ||
| Q1 24 | 11.9% | 7.6% |
| Q4 25 | 12.1% | 7.3% | ||
| Q3 25 | 23.6% | 7.3% | ||
| Q2 25 | 21.3% | 4.5% | ||
| Q1 25 | 14.5% | 6.0% | ||
| Q4 24 | 10.1% | 1.0% | ||
| Q3 24 | 21.3% | 2.7% | ||
| Q2 24 | 20.2% | 0.3% | ||
| Q1 24 | 11.5% | 3.2% |
| Q4 25 | $0.78 | $0.67 | ||
| Q3 25 | $2.26 | $0.65 | ||
| Q2 25 | $1.76 | $0.43 | ||
| Q1 25 | $1.10 | $0.51 | ||
| Q4 24 | $0.72 | $0.08 | ||
| Q3 24 | $2.12 | $0.17 | ||
| Q2 24 | $1.71 | $0.02 | ||
| Q1 24 | $0.95 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $215.7M | $74.5M |
| 総負債低いほど良い | $3.3B | $624.2M |
| 株主資本純資産 | $3.6B | $332.4M |
| 総資産 | $10.2B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.93× | 1.88× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $215.7M | $74.5M | ||
| Q3 25 | $333.2M | $85.3M | ||
| Q2 25 | $474.5M | $77.0M | ||
| Q1 25 | $634.5M | $70.4M | ||
| Q4 24 | $368.9M | $67.1M | ||
| Q3 24 | $427.9M | $89.8M | ||
| Q2 24 | $169.6M | $114.6M | ||
| Q1 24 | $157.6M | $98.7M |
| Q4 25 | $3.3B | $624.2M | ||
| Q3 25 | — | $628.0M | ||
| Q2 25 | — | $631.7M | ||
| Q1 25 | — | $635.4M | ||
| Q4 24 | $3.1B | $639.1M | ||
| Q3 24 | — | $295.2M | ||
| Q2 24 | — | $312.1M | ||
| Q1 24 | — | — |
| Q4 25 | $3.6B | $332.4M | ||
| Q3 25 | $3.5B | $311.7M | ||
| Q2 25 | $3.4B | $285.7M | ||
| Q1 25 | $3.3B | $266.0M | ||
| Q4 24 | $3.3B | $246.8M | ||
| Q3 24 | $3.3B | $258.5M | ||
| Q2 24 | $3.2B | $256.6M | ||
| Q1 24 | $2.9B | $270.1M |
| Q4 25 | $10.2B | $1.4B | ||
| Q3 25 | $10.1B | $1.4B | ||
| Q2 25 | $9.9B | $1.4B | ||
| Q1 25 | $9.6B | $1.3B | ||
| Q4 24 | $9.2B | $1.3B | ||
| Q3 24 | $9.1B | $966.3M | ||
| Q2 24 | $8.7B | $982.2M | ||
| Q1 24 | $8.3B | $979.0M |
| Q4 25 | 0.93× | 1.88× | ||
| Q3 25 | — | 2.01× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | 0.92× | 2.59× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $137.8M | $19.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $-216.2M | $8.3M |
| FCFマージンFCF / 売上 | -60.0% | 2.2% |
| 設備投資強度設備投資 / 売上 | 98.3% | 3.0% |
| キャッシュ転換率営業CF / 純利益 | 3.16× | 0.70× |
| 直近12ヶ月FCF直近4四半期 | $-577.5M | $47.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $137.8M | $19.4M | ||
| Q3 25 | $162.8M | $9.3M | ||
| Q2 25 | $176.9M | $21.3M | ||
| Q1 25 | $124.3M | $43.2M | ||
| Q4 24 | $136.4M | $3.1M | ||
| Q3 24 | $201.9M | $12.6M | ||
| Q2 24 | $146.4M | $28.4M | ||
| Q1 24 | $109.7M | $11.4M |
| Q4 25 | $-216.2M | $8.3M | ||
| Q3 25 | $-127.9M | $-4.5M | ||
| Q2 25 | $-156.4M | $8.1M | ||
| Q1 25 | $-77.0M | $35.4M | ||
| Q4 24 | $-48.9M | $-4.7M | ||
| Q3 24 | $-16.1M | $3.0M | ||
| Q2 24 | $-199.6M | $15.4M | ||
| Q1 24 | $-150.3M | $1.7M |
| Q4 25 | -60.0% | 2.2% | ||
| Q3 25 | -24.3% | -1.2% | ||
| Q2 25 | -34.8% | 2.1% | ||
| Q1 25 | -18.7% | 10.2% | ||
| Q4 24 | -13.0% | -1.5% | ||
| Q3 24 | -3.0% | 1.2% | ||
| Q2 24 | -45.1% | 5.6% | ||
| Q1 24 | -36.0% | 0.6% |
| Q4 25 | 98.3% | 3.0% | ||
| Q3 25 | 55.2% | 3.8% | ||
| Q2 25 | 74.2% | 3.5% | ||
| Q1 25 | 49.0% | 2.2% | ||
| Q4 24 | 49.3% | 2.5% | ||
| Q3 24 | 41.0% | 3.7% | ||
| Q2 24 | 78.2% | 4.8% | ||
| Q1 24 | 62.2% | 3.7% |
| Q4 25 | 3.16× | 0.70× | ||
| Q3 25 | 1.31× | 0.35× | ||
| Q2 25 | 1.85× | 1.24× | ||
| Q1 25 | 2.08× | 2.07× | ||
| Q4 24 | 3.60× | 0.97× | ||
| Q3 24 | 1.78× | 1.81× | ||
| Q2 24 | 1.63× | 37.80× | ||
| Q1 24 | 2.28× | 1.36× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IDA
| Retailrevenues | $323.0M | 90% |
| Transmissionserviceswheeling | $18.6M | 5% |
| Energyefficiencyprogramrevenues | $11.7M | 3% |
| Wholesaleenergysales | $10.5M | 3% |
| Otherrevenues | $9.5M | 3% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
